Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the <scp>UK National Cancer Research Institute</scp> phase <scp>II</scp> / <scp>III GALACTIC</scp> trial-Reference-Cited by-同舟云学术

Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II / III GALACTIC trial

Published:2022-08-26 Issue:5 Volume:199 Page:707-719
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Munir Talha¹^ORCID,Emmerson Jake²,Hockaday Anna²,Oughton Jamie B.²,Howard Dena²^ORCID,Phillips David²,Neilson Jeff³,Pemberton Nicholas⁴,Paneesha Shankara⁵,Kennedy Ben⁶,Rawstron Andy⁷,Hillmen Peter¹⁸^ORCID

Affiliation:

1. St James's Institute of Oncology, St James's University Hospital Leeds UK

2. Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds Leeds UK

3. Russell Hall Hospital Dudley UK

4. Worcestershire Royal Hospital Worcestershire UK

5. Birmingham Heartlands Hospital Birmingham UK

6. Leicester Royal Infirmary Leicester UK

7. Haematological Malignancy Diagnostic Service, St James's Institute of Oncology, St James's University Hospital Leeds UK

8. Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds Leeds UK

Funder

F. Hoffmann-La Roche

University of Leeds

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18427

Reference28 articles.

1. CANCER RESEARCH UK.Chronic lymphocytic leukaemia (cll) incidence statistics2016.

2. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

3. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

4. Minimal residual disease is an independent predictor for 10-year survival in CLL

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials;Frontiers in Oncology;2023-02-22